Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for neoadjuvant treatment of refractory hepatocellular carcinoma and adjuvant treatment in high-risk postoperative recurrence
ChiCTR2000040392Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: R0 resection rate. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040392.